The Society of Cancer Management
  • Home
    • An After Life
    • News Archive
  • About
    • Terms & Conditions
    • Privacy Policy
    • Copyright Notice
  • Contact

. . . supporting research that improves cancer survival.

 
Please contact us if you would like to contribute a news item. We are keen to publish more articles from UK-based research and findings that relate to microbial infections during therapy.

Toxic mushroom-based drug may help battle colorectal cancer

23/4/2015

0 Comments

 
For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

Researchers at The University of Texas MD Anderson Cancer Center looked at antibody drug conjugates (ADCs) based on alpha-amanatin as one solution. They found that ADCs, when aimed at a gene called POLR2A, are highly effective in mouse studies in treating colorectal cancer. The drug caused complete tumor regression and greatly reduced toxicity. ADCs allow for improved targeting of cancer cells, resulting in less impact on healthy cells.

Xiongbin Lu, Ph.D., associate professor of Cancer Biology, observed that when the common tumor suppressor gene, TP53 is deleted resulting in cancer growth, another nearby gene, POLR2A is also deleted. Normal cells have two copies of POLR2A and TP53 genes. Lu's study targeted cancers that had a single copy of both genes, representing 53 percent of colorectal cancers, 62 percent of breast cancers and 75 percent of ovarian cancers.

"POLR2A is an essential gene for cell survival, including cancer cells," said Lu. "Because there is only one copy, the cancer cells are more susceptible to suppression of this gene."

Lu's study was published in the April 22, 2015 issue of Nature.

Read More
0 Comments

Cancer scan could remove the need for radiotherapy in some patients

23/4/2015

0 Comments

 
A UK National Cancer Research Institute trial led from The University of Manchester and the Christie NHS Foundation Trust has suggested that in patients with early stage Hodgkin lymphoma the late effects of radiotherapy could be reduced by using a scan to determine those who actually need it.

In a paper published in the New England Journal of Medicine, the researchers show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

Hodgkin lymphoma is a cancer that develops in the lymphatic system, which is a network of vessels and glands spread throughout the body. Around 1,900 people a year, many of whom are teenagers and young adults, are diagnosed in the UK.

The current standard treatment is for all Hodgkin lymphoma patients to receive chemotherapy, followed by radiotherapy. However, this radiotherapy comes with undesirable late effects, such as cardiovascular disease and other cancers - despite the fact that they have already been cured of Hodgkin lymphoma.

The 602 patients who agreed to take part in the 'RAPID' trial had a PET scan performed after their chemotherapy. Patients who tested positive received radiotherapy. Those who tested negative were divided into two groups - one group of 211 patients received no further treatment, while the other group of 209 had the standard radiotherapy.

After three years of regular check-ups, the proportion of patients who were alive and free of disease was 94.6% in the radiotherapy group, and 90.8% in the group which hadn't received further treatment.

Read More
0 Comments

Triple negative breast cancer in African-American women has distinct difference

23/4/2015

0 Comments

 
What makes triple negative breast cancer more lethal in African American women than White women or women of European descent? A new study reveals specific genetic alterations that appears to impact their prognosis and ultimately survival rates. The study will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia.

Luciane R. Cavalli, PhD, assistant professor at Georgetown Lombardi Comprehensive Cancer Center explains this new work:

"Triple negative breast cancer is an aggressive subtype of breast cancer where limited treatment is available. These tumors are the leading cause of breast cancer death in African-American women, which are usually diagnosed at an earlier age and in more advanced stages of the disease, when compared with White women. The main objective of our study was to identify molecular markers in these patients that may be associated with their observed disparity in incidence and mortality rates."
"Using genome-wide screening methods, we identified a distinct pattern of DNA copy number (genome regions with gains and losses) and miRNA (small non-coding regions in the genome) expression levels associated significantly with the African American triple negative breast cancer patients, when compared with White TNBC patients. This association was observed irrespectively of their clinical and pathological characteristics, including age, tumor size, stage and grade and presence of axillary lymph node metastasis."

"These initial findings indicate specific genetic alterations, involved in critical cancer related pathways and networks, in the triple negative breast cancer of African American women that might present an impact for their prognosis and treatment, ultimately contributing to an increase in their overall survival rate."

American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia.
0 Comments

Physical activity benefits lung cancer patients and survivors

4/4/2015

0 Comments

 
Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer.

Lung cancer is the leading cause of cancer deaths in the United States with an estimated 160,000 deaths each year and worldwide there are 1.4 million deaths. In the last two decades lung cancer therapy has improved, but the overall 5-year survival rate is still quite low at 17%. Lung cancer patients experience many debilitating symptoms including difficulty breathing, cough, fatigue, anxiety, depression, insomnia, and pain. A third of long term survivors, those >5 years from diagnosis, experience reduced quality of life and report lower physical and health scores compared to healthy patients. Given the incidence of lung cancer and the associated costs An inexpensive and relatively easy cancer therapy to reduce symptoms and improve quality of life, like physical activity, could be beneficial, especially for therapy, but clinicians underutilize exercise as a therapy, in part due to the lack of evidence-based consensus as to how and when to implement increasing physical activity.

Dr. Gerard A. Silvestri, Dr. Brett Bade, and colleagues at Medical University of South Carolina have reviewed the safety, benefits, and application of increasing physical activity and exercise in lung cancer with the goal to summarize the effect on improved lung cancer outcomes. Their results are published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC).

Read More
0 Comments

Future Science Group announces free access to peer-reviewed journals focused on cancer

4/4/2015

0 Comments

 
Future Science Group today announced that it will provide free access to three of its peer-reviewed, cancer-focused journals for the remainder of 2015. The journals, Hepatic Oncology, Melanoma Management, and the International Journal of Endocrine Oncology present the latest findings in their area of research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field.

"Given the critical importance of emerging research to every practitioner treating patients with cancer, we are very pleased to provide individuals with better access to new sources of quality information," said Phil Garner, Managing Director of Future Science Group. "While the journals are relatively new, each offers in depth coverage of an area of cancer that demands more attention and resources."

Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The quarterly journal also highlights significant advances in basic and translational research, and places them in context for future therapy.

For more details please see: http://www.futuremedicine.com/loi/hep

Melanoma Management launched in August 2014 and focuses on the clinical aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. Published quarterly, Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.

For more details please see: http://www.futuremedicine.com/loi/mmt

International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in a fast-moving field that covers a broad range of diseases, both malignant and benign. It presents research findings in diagnosis and management of endocrine cancer, including tumors of hormone-secreting glands, such as the pituitary, thyroid, pancreatic and adrenal glands, along with neuroendocrine tumors. Independent drug evaluations assess newly approved medications and their role in clinical practice.

For more details please see: http://www.futuremedicine.com/loi/ije

All of the journals welcome the unsolicited submission of article proposals and original research manuscripts. Select content can be accessed from the whole of Future Science Group's Oncology collection. Plus, via Oncology Central, Future Science Group's free eCommunity for oncology professionals, users can access breaking news, articles and other essential current information, all aimed and selected by fellow trusted clinicians.

0 Comments

Avoid eating herring and mackerel during chemotherapy

4/4/2015

0 Comments

 
Researchers found that consuming the fish herring and mackerel, as well as three kinds of fish oils, raised blood levels of the fatty acid 16:4(n-3), which experiments in mice suggest may induce resistance to chemotherapy used to treat cancer, according to a study published online by JAMA Oncology.

Patients with cancer often adopt lifestyle changes and those changes often include the use of supplements. But there is growing concern about the use of supplements while taking anticancer drugs and the possible effect on treatment outcomes, according to the study background.

Emile E. Voest, M.D., Ph.D., of the Netherlands Cancer Institute, Amsterdam, and coauthors examined exposure to the fatty acid 16:4(n-3) after eating fish or taking fish oil.

The authors examined the rate of fish oil use among patients undergoing cancer treatment, while researchers also recruited healthy volunteers to examine blood levels of the fatty acid after ingestion of fish oils and fish. The fish oil portion included 30 healthy volunteers and the fish portion included 20 healthy volunteers.

Read More
0 Comments

    Cancer Therapy & Palliative Care News

    This feed features recent developments in cancer therapy and palliative care. Views in these articles do not necessarily represent those of the Cancer Management Society.

    Archives

    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013

    Categories

    All
    General
    Presentation
    Research
    Review

    RSS Feed

Home

About

Contact Us

Terms & Conditions

Privacy Policy

Copyright Notice

RSS Feed

Proudly powered by Weebly
© The Society of Cancer Management 2017